REMARKS

The specification has been amended to recite the priority data, to cancel claims 1-16 of the PCT application, and to add new claims 17-33. Support for the new claims is found in the specification and claims as originally filed. No new matter is added by this amendment. The filing fee has been calculated after amendment of the claims by the preliminary amendment.

The specification has also been amended to add sequence identifiers for four sequences disclosed on pages 13 and 14 of the specification that did not include the required sequence identifiers. Further, a substitute Sequence Listing containing these four sequences (SEQ ID NO: 16-19) has been submitted herewith, together with an amendment directing its entry into the specification. No new matter is introduced by this amendment.

Should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/SONN:066US.

Respectfully submitted

Mark B. Wilson Reg. No. 37,259

Attorney for Applicant

(Customer No. 32425) FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 512.536.3035 (voice) 512.536.4598 (fax)

Date:

January 12, 2005